The Taskforce has issued a consensus recommendation to consider increased-dose venous thromboembolism (VTE) prophylaxis for adults with severe to critical COVID-19. This recommendation was developed with input from thrombosis specialists on the Taskforce’s new Expert Advisory Group. A number of case series and cohort studies have been published showing a high incidence of VTE despite standard VTE prophylaxis. While there have been no trials of VTE prophylaxis dosing in COVID-19 to date, the consensus of the Taskforce is that given the high rates of VTE, the potential benefits of increased-dose VTE prophylaxis outweigh the known risks.
Increasingly, we will see the publication of larger studies of COVID-19 clinical care with a significant impact on practice. This week, the evidence teams reviewed the interim results of a remdesivir trial published in the New England Journal of Medicine, adding these data to another remdesivir trial published recently in The Lancet. Updated recommendations are expected to be made next week.
We welcomed Rebecca Randall and Satrio Nindyo (Tiko) Istiko as Consumer Representatives on the Guidelines Leadership Group, and are very pleased to announce the formation of our Consumer Panel in partnership with Consumers Health Forum. Rebecca and Tiko will co-chair the Consumer Panel.
The Palliative and Aged Care Panel has now formed and is scheduled to meet for the first time next week.
We are pleased to announce a formal partnership with the Australian Commission on Safety and Quality in Health Care. We look forward to working closely with the Commission to ensure there is consistency of advice and guidance around the safe and effective clinical care for COVID-19.
We are currently reviewing evidence to develop recommendations and flowcharts to guide practice in areas including:
Each week we collect suggestions for new clinical questions or topics for consideration by the Taskforce. A document that lists all of the suggested questions, topics and new patient groups that we have received to date is available on the website and updated each week.
We are currently working with a number of other agencies including the Infection Control Expert Group (ICEG) to ensure that questions or topics deemed out of scope for the Taskforce can be raised with agencies who can respond appropriately.
New suggestions considered potentially in scope for the Taskforce this week included:
Suggested new clinical questions
Suggested new topics
It is a core mission of the Taskforce to engage with frontline clinicians to rapidly identify and address priority clinical questions. Please encourage your clinical colleagues to provide their insights via the website.
New rapid reviews published: